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DNA methylation is important in regulating gene expression and genomic stability while 2 
aberrant DNA methylation is associated with disease. Riboflavin (FAD) is a cofactor for 3 
methylenetetrahydrofolate reductase (MTHFR), a critical enzyme in folate recycling, which 4 
generates methyl groups for homocysteine remethylation to methionine, the pre-cursor to the 5 
universal methyl donor S-adenosylmethionine (SAM). A polymorphism (C677T) in MTHFR 6 
results in decreased MTHFR activity and increased homocysteine concentration. Previous 7 
studies demonstrated that riboflavin modulates this phenotype in homozygous adults 8 
(MTHFR 677TT genotype), however, DNA methylation was not considered. This study 9 
examined DNA methylation, globally and at key MTHFR regulatory sites, in adults stratified 10 
by MTHFR genotype and the effect of riboflavin supplementation on DNA methylation in 11 
individuals with the 677TT genotype. Samples were accessed from participants, screened for 12 
the MTHFR C677T polymorphism, who participated in observational (n = 80) and targeted 13 
riboflavin (1.6mg/day) RCTs (n = 80). DNA methylation at LINE-1 and key regulatory 14 
regions of the MTHFR locus were analysed by pyrosequencing in peripheral blood 15 
leukocytes. LINE-1 (+1.6%; p = 0.011) and MTHFR south shelf (+4.7%, p < 0.001) were 16 
significantly hypermethylated in individuals with the MTHFR 677TT compared to CC 17 
genotype. Riboflavin supplementation resulted in decreased global methylation, albeit only 18 
significant at one CpG. A significant reduction in DNA methylation at the MTHFR north 19 
shore (-1.2%, p < 0.001) was also observed in TT adults following intervention with 20 
riboflavin. This provides the first RCT evidence that DNA methylation may be modulated by 21 
riboflavin in adults with the MTHFR 677TT genotype.  22 
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1. INTRODUCTION  26 
DNA methylation involves the addition of a methyl group to the 5’ position of a cytosine and 27 
usually occurs at CpG dinucleotides. Global methylation influences genome stability while 28 
gene-specific methylation leads to transcription changes influencing gene expression and 29 
phenotypes [1,2]. Differential methylation has also been shown to occur at CpG island shores 30 
(~ 2kb outwards from CpG islands) and shelves (~ 2kb outwards from island shores) [3]. 31 
Alterations in methylation at these key regulatory regions influence phenotypes and 32 
contribute to disease risk [4]. Variations in DNA methylation can occur throughout the 33 
lifetime of an individual and have important consequences for health and disease [5–7]. DNA 34 
methylation is responsive to environmental changes [8] such as alterations in diet and this 35 
provides a mechanism through which epigenetic modulation can influence health outcomes.  36 
One-carbon metabolism (Figure 1), is the main metabolic pathway through which nutrients, 37 
mainly folate and related B-vitamins, interact to modulate DNA methylation [9–13]. Factors 38 
influencing intake or metabolism of these nutrients including common polymorphisms within 39 
genes that influence the one-carbon pathway may therefore impact methylation reactions 40 
[14]. Riboflavin in the form of flavin adenine dinucleotide (FAD) is a cofactor for MTHFR, a 41 
critical enzyme in one-carbon metabolism and thus for the production of S-42 
adenosylmethionine (SAM), the universal methyl donor. Riboflavin has been largely 43 
overlooked in studies investigating B-vitamins in relation to DNA methylation. Of the few 44 
reports focusing on riboflavin, an observational study of pregnant Gambian women showed 45 
that riboflavin was a significant predictor of peripheral blood DNA methylation at six 46 
metastable epialleles (BOLA3, LOC654433, EXD3, ZFYVE28, RBM46, PARD6G and 47 
ZNF678) the offspring [15]. A recent cross-sectional study also reported an inverse 48 
association between dietary riboflavin intake and LINE-1 methylation in peripheral blood 49 
[16] while another study observed a positive correlation between daily intake of riboflavin 50 
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and LINE-1 methylation in white blood cells [17]. The latter studies relied on food frequency 51 
questionnaires to estimate riboflavin intake which may not accurately reflect status and as 52 
such, biomarker concentrations are a much more reliable indicator to investigate the 53 
relationship between riboflavin status and DNA methylation [13,18]. Furthermore, limited 54 
conclusions can be drawn from observational data which highlights the need for randomised 55 
controlled trials to determine the effects of one-carbon metabolism nutrients on epigenetic 56 
mechanisms. 57 
The C677T polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene is one 58 
of the most widely studied polymorphisms in relation to one-carbon metabolism and health 59 
and disease [19]. It involves a C to T transition at position 677 which causes a substitution of 60 
alanine with valine resulting in a thermolabile MTHFR enzyme with decreased enzyme 61 
activity in individuals homozygous for the genotype [20] due to the loss of affinity for its 62 
cofactor FAD [21]. Polymorphisms and reduced enzyme activity of MTHFR are linked to 63 
various diseases  [22–24] however only a small number of studies conducted in mice and 64 
humans have examined the MTHFR epigenetic landscape and gene expression [25,26]. 65 
Aberrant hypermethylation of key regulatory regions surrounding the MTHFR CpG island 66 
have been uncovered in human paediatric astrocytomas [25]. In mice, reduced levels of 67 
MTHFR resulting from homozygous or heterozygous genetic deletion, resulted in decreased 68 
SAM levels or significantly increased S-adenosylhomocysteine (SAH) levels, or both, and 69 
global DNA hypomethylation. [27]. Therefore, other factors which potentially alter MTHFR 70 
levels, such as riboflavin supplementation, may also impact global and gene-specific DNA 71 
methylation. Our hypothesis was that DNA methylation differed in adults stratified by the 72 
MTHFR C667T genotype, could be modulated by supplementation with riboflavin, the 73 
MTHFR cofactor, in those with TT genotype. To test this hypothesis, we examined 74 
differences in global and gene-specific methylation at key regulatory sites at the MTHFR 75 
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locus in adults stratified by the MTHFR C677T genotype. Furthermore, we examined the 76 
effect of riboflavin supplementation on DNA methylation in adults with the MTHFR 677TT 77 
genotype. 78 
 79 
2. MATERIALS AND METHODS 80 
2.1. Participants and Sample Selection 81 
Samples for this study were accessed from stored buffy coat samples from participants who 82 
were screened for the MTHFR C677T polymorphism and had consented and participated in 83 
targeted double-blind randomised controlled trials previously conducted at the Nutrition 84 
Innovation Centre for food and Health (NICHE) at Ulster University, Northern Ireland. 85 
Samples were drawn from three cohorts namely, the Genetic and Vitamin study (Genovit - 86 
FCBMA-15-070), the Genetic and Vitamin ten year follow up study (GENOVIT10 -87 
UUREC/12/0338) and the optimization of RIBOflavin Status in Hypertensive Adults with a 88 
Genetic predisposition to Elevated Blood pressure study (RIBOGENE - REC/12/0136) to 89 
enable the required number of age and sex matched samples from placebo and treatment 90 
groups to be accessed. Each of these studies were conducted using a standardised protocol.  91 
Furthermore, each study had identical inclusion and exclusion criteria which included history 92 
of gastrointestinal, hepatic, renal or haematological disorders, usage of B-vitamin 93 
supplements, anticonvulsant therapy or any other drugs known to interfere with folate or B-94 
vitamin metabolism. Additional ethical approval was granted by Office of Research and 95 
Ethics Northern Ireland for the analysis reported in this current study. Data on lifestyle 96 






2.2. Study Design 101 
Analysis for this study was carried out in two stages: in an observational stage (n = 80), DNA 102 
methylation differences were examined between the two MTHFR C677T genotypes (i.e. 103 
677CC and 677TT) and in an intervention stage (n = 80). DNA methylation was examined in 104 
response to supplementation with either riboflavin (1.6mg/d) or placebo for 16 weeks in 105 
individuals with the MTHFR 677TT genotype only. Appropriate samples of intervention with 106 
riboflavin in CC participants, were not available for the current analysis from the only study 107 
[28] to date to have conducted a riboflavin intervention in all three MTHFR 677 genotype 108 
groups. Participants were age- and sex-matched for both the observational and intervention 109 
stages of the study (Table 1). The flow diagram of the study design is illustrated in Figure 2.  110 
2.3. Biomarker Status 111 
Blood samples were analysed by standard laboratory assays for total homocysteine and 112 
riboflavin biomarker status as reported in previous studies [28,29]. Riboflavin status was 113 
determined using the erythrocyte glutathione reductase coefficient (EGRac), a functional 114 
assay which measures the activity of glutathione reductase before and after in vitro reaction 115 
with its prosthetic group flavin adenine dinucleotide (FAD). EGRac is calculated as a ratio of 116 
FAD-stimulated to -unstimulated enzyme activity with higher values indicative of lower 117 
riboflavin status and is recognised as the gold standard. Values of EGRac at or above 1.3 are 118 
generally indicative of suboptimal riboflavin status [30,31]. 119 
2.4. DNA Methylation Analysis 120 
2.4.1. ENCODE dataset analysis 121 
The Infinium 450K Bead Array and DNA methylation data from the ENCODE consortium 122 
available as user tracks in UCSC genome browser were utilized in this study [32]. The 123 
MTHFR genomic region “Chr1:11,868,000-11,862,000” (hg19) was inspected for differential 124 
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DNA methylation. In order to determine appropriate locations of gene-specific 125 
pyrosequencing assays for MTHFR gene regulatory regions, we carried out an analysis of 126 
DNA methylation at the region surrounding the MTHFR transcription start site (Chr1: 127 
11,868,000-11,862,000) in USCS genome browser (hg19) using publicly available Infinium 128 
HumanMethylation450 BeadChip methylation data from the ENCODE project [32].  This 129 
analysis showed that the north shore and south shelf MTHFR gene regulatory regions are 130 
variably methylated in five different human cell lines (Supplementary Figure 1) while the 131 
CpG island itself is largely unmethylated.  The base pair resolution of these datasets allowed 132 
us to accurately target the chromosomal region likely to be susceptible to variable DNA 133 
methylation. Using the above information, we next experimentally investigated the 134 
chromosomal regions for methylation change by pyrosequencing analysis in our human 135 
samples. 136 
2.4.2. Genomic DNA extraction 137 
Genomic DNA was extracted from 200µl of stored peripheral blood leukocyte samples using 138 
the Qiagen QIAamp DNA blood mini kit (Qiagen, UK). The process was carried out 139 
according to the manufacturer’s protocol [33]. The extracted genomic DNA samples were 140 
electrophoresed on a 1% (w/v) agarose gel to examine their quality. The purity, and 141 
concentration of DNA samples was quantified using the NanodropND1000 142 
spectrophotometer (Labtech International, Ringmer, UK). 143 
2.4.3. Bisulphite Conversion of Genomic DNA 144 
Subsequent bisulphite conversion of 500ng of genomic DNA was carried out according to the 145 
manufacturer’s instructions [34–36] using the EZ DNA methylation kit (Zymo Research 146 





2.4.4. Polymerase Chain Reaction and Pyrosequencing 150 
DNA methylation at the Long Interspersed Nuclear Elements (LINE-1) was measured as a 151 
surrogate marker for global methylation. The LINE-1 (GenBank accession number 152 
X58075.1) assay covered 3 CpG sites. Three regions of the MTHFR gene (GenBank 153 
accession: NM_001330358.1), covering the north shore, south shelf and the CpG island 154 
promoter were examined in this study. Commercially available assays for LINE-1 (970042) 155 
and MTHFR CpG island (PM00000091) promoter from Qiagen UK were used for PCR of 156 
bisulphite treated DNA. Primers for MTHFR north shore (Chr1: 11867263-11867362) and 157 
south shelf (Chr1: 11862886-11862985) were designed using PyroMark Assay Design 158 
software 2.0. Assay regions were chosen to align with publicly available Illumina 450k array 159 
data deposited in UCSC Genome Browser which displayed varying levels of DNA 160 
methylation in various cell lines: Primers for the commercially available LINE-1 assay and 161 
MTHFR CpG island covered 3CpGs each while in-house designed primers for the MTHFR 162 
north shore and south shelf covered only one CpG due to technical difficulties in primer 163 
design. MTHFR north shore forward: 5’ TTTGGGTAATTAAAGTAGTGAGTGGTTTG 3’ 164 
and MTHFR north shore reverse: 5’ CCCTAAAACAAAAAATCAAAAAACATCTCT 3’; 165 
MTHFR south shelf forward: 5’ CCCTAAAACAAAAAATCAAAAAACATCTCT 3’ and 166 
MTHFR souths shelf reverse: 5 ’TCCCCAAACACCACCACT 3’. The PyroMark PCR kit 167 
(Qiagen UK) was used for generating amplicons. Each 25µl reaction mix consisted of 12.5µl 168 
master mix, 2.5µl coral load, 5.5µl nuclease-free water, 1.25µl each of 10µM forward and 169 
reverse primers (2.5µl for commercial primers) and 2µl each of bisulphite converted DNA. 170 
PCR was then carried out under the following conditions: initial hot start, 95⁰C for 15 171 
minutes, followed by 45 cycles of 94⁰C for 30 seconds, 56⁰C for 30 seconds, 72⁰C for 30s 172 
and a final elongation of 10 minutes at 72⁰C. The PCR products were subsequently 173 
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electrophoresed on a 1% (w/v) agarose gel electrophoresis to check the size of DNA 174 
fragments and also as a quality control measure to check samples for contamination. 175 
DNA methylation levels in samples were analysed using the PyroMark Q24 pyrosequencing 176 
instrument (Qiagen, UK). Enzymes, substrates and nucleotides from the PyroMark Gold Q24 177 
kit (Qiagen UK) were used.  Built in controls within assays to be analysed were used to verify 178 
bisulphite conversion. Levels of methylation at each CpG site were analysed using the 179 
PyroMark Q24 software [37,38]. The degree of methylation at each CpG site is expressed as 180 
the percentage of methylated cytosine over the sum of methylated and unmethylated cytosine. 181 
The degree of methylation is reported for each CpG analysed as well as the average 182 
percentage of methylation across CpG sites. To verify the accuracy of the analysis, control 183 
DNA from EpiTect PCR (Qiagen UK) containing human bisulphite converted fully 184 
methylated or unmethylated DNA were included as positive and negative controls in the 185 
pyrosequencing runs. 186 
 187 
2.5. Statistical Analysis  188 
For the current analysis, power calculations to determine sample size were carried out using 189 
the G Power 3.1.9.4 software (version 3) [39] statistical power calculator.  Based on power 190 
calculations using data from Bollati and colleagues [40], it was estimated that 39 participants 191 
per group would be able to discriminate differences of 3.4% in DNA methylation with a 192 
power of 80%, at α = 0.05 and effect size of 0.65. This sample size is similar to that reported 193 
in previous studies investigating folic acid and vitamin B-12 supplementation and DNA 194 
methylation [41,42]. Statistical analysis of data was conducted using SPSS IBM Statistics 195 
(version 25, SPSS UK Ltd Chertsey, UK). The normality of continuous variables was 196 
confirmed using QQ-plots and the Kolmogorov-Smirnov test. All tests were carried out at the 197 
95% confidence interval and in all analyses p < 0.05 was considered statistically significant.  198 
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Methylation values are shown for all loci analysed and an average methylation for the three 199 
CpG sites analysed for the LINE-1 and MTHFR CpG island assay. The assays for the 200 
MTHFR north shore and south shelf contained one CpG. Change in methylation in response 201 
to riboflavin supplementation was calculated as the difference between post-intervention and 202 
baseline methylation values for each CpG analysed and the average.  203 
Chi-square tests for independence were used for comparing categorical variables such as sex, 204 
smoking and hypertensive status. Continuous variables including age and body mass index 205 
(BMI), were analysed using independent t-tests. One-way analysis of covariance (ANCOVA) 206 
adjusted for age, sex, smoking status and study cohort was used to analyse DNA methylation 207 
stratified by MTHFR C677T genotypes at baseline. Biomarker (EGRac and homocysteine) 208 
responses to intervention with riboflavin were examined using mixed between-within 209 
repeated measures ANOVA. The time × treatment interaction was used to assess the effect of 210 
treatment versus placebo over time. The between-patient factor was the intervention group 211 
(placebo versus riboflavin), and the within-patient factor was time (pre- and post-212 
supplementation). Mixed between-within repeated measures ANCOVA was used to analyse 213 
the effect of riboflavin supplementation on DNA methylation in individuals with the MTHFR 214 
677TT genotype. The time × treatment interaction was used to assess the effect of treatment 215 
versus placebo over time. The between factor was the intervention group (riboflavin versus 216 
placebo) with time (pre- and post- intervention) as the within factor. The mixed between-217 
within analysis tests whether there are main effects for each independent variable and 218 
whether the interaction between the two variables is significant. The analysis was further 219 
adjusted as appropriate for confounders previously reported to influence DNA methylation 220 
such as age, sex, smoking status and study cohort. To account for multiple testing, the level 221 
of significance (P < 0.05) was adjusted for Bonferroni correction at the assay level (n = 4 for 222 
LINE-1, n = 6 for MTHFR north shore, south shelf and CpG island DNA methylation), 223 
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therefore P < 0.0125 or P < 0.008 was considered statistically significant where appropriate. 224 
Pearson’s bivariate correlation coefficient (r), was used to estimate correlations between 225 
riboflavin biomarker and DNA methylation in individuals with the TT genotype in the 226 
intervention study stratified by treatment groups.    227 
3. RESULTS 228 
3.1. General Characteristics of Participants 229 
A total of 80 participant samples were analysed in the observational stage of the study 230 
examining both global methylation and gene-specific methylation, the latter at the MTHFR 231 
north shore, south shelf and CpG island, in individuals stratified by MTHFR C677T 232 
genotype. Individuals with the CC genotype were age- and sex-matched to individuals with 233 
the MTHFR 677TT genotype (Figure 2). The characteristics of participants in the 234 
observation study are described in Table 1. Generally, participants were on average 57 years 235 
old and no statistically significant differences were observed between MTHFR C677T 236 
genotype groups in relation to baseline characteristics such as age, sex, BMI and smoking 237 
status. Riboflavin biomarker status was not significantly different between treatment groups 238 
prior to intervention.  239 
3.2. Differences in DNA methylation in individuals stratified by MTHFR C677T 240 
genotype 241 
There was a general trend towards higher methylation both globally and at sites assayed 242 
across the MTHFR locus in individuals with the MTHFR 677TT genotype in comparison to 243 
the CC genotype group (Table 2). Perhaps surprisingly, global DNA methylation measured 244 
by LINE-1 was significantly higher (+1.6%; p = 0.011) in participants with the MTHFR 245 
677TT genotype compared to those with the CC genotype at baseline. Additionally, 246 
significant hypermethylation was detected in individuals with the MTHFR 677TT genotype at 247 
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the MTHFR south shelf (+4.85%, p < 0.001) compared to CC individuals. DNA methylation 248 
at the MTHFR north shore and CpG island were however not significantly different between 249 
genotype groups at baseline, although there was again a trend for higher methylation in 250 
individuals with the MTHFR 677TT genotype.  251 
 252 
3.3. Effect of riboflavin supplementation on biomarker status 253 
The biomarker responses to riboflavin intervention are shown in Table 3. As expected, 254 
riboflavin biomarker status in adults with the MTHFR 677TT genotype improved in response 255 
to riboflavin supplementation (P < 0.001), as indicated by a mean decrease in the functional 256 
biomarker EGRac in participants who received riboflavin (-0.10 ± 0.01) compared to placebo 257 
(0.02 ± 0.01). Furthermore, there was a significant reduction in homocysteine concentrations 258 
(P = 0.001) in the group supplemented with riboflavin (-1.79 ± 3.50 μmol/L) compared to 259 
placebo (-0.42 ± 3.10 μmol/L). 260 
3.4. Effect of riboflavin supplementation on global and gene-specific methylation in 261 
MTHFR 677TT participants 262 
Investigation of the effect of riboflavin supplementation on DNA methylation in individuals 263 
with the MTHFR 677TT genotype indicated decreased  average methylation at LINE-1 264 
(Riboflavin: -3.16% ± 0.91% vs. Placebo: -0.32% ± 0.69%, P = 0.018) which  remained 265 
significant following Bonferroni correction at CpG 2 (Riboflavin: -1.49% ± 0.72% vs. 266 
Placebo : 1.23% ± 0.62%, P = 0.006). The MTHFR north shore was significantly 267 
hypomethylated (-1.24% ± 0.50% vs. 0.90% ± 0.50%, P = 0.001) in participants 268 
supplemented with riboflavin compared to placebo respectively.  Methylation at the MTHFR 269 
south shelf and CpG island in individuals with the MTHFR 677TT genotype group was not 270 
influenced by supplementation with riboflavin or placebo. Furthermore, we observed a non-271 
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significant trend for a positive correlation between riboflavin biomarker status and LINE-1 272 
DNA methylation in the riboflavin group compared to the placebo however this was not 273 
significant (Figure 3). A similar non-significant correlation was observed for riboflavin 274 
biomarker and MTHFR north shore methylation (data not shown).   275 
   276 
4. DISCUSSION 277 
The current study provides the first RCT evidence that supplementation with riboflavin 278 
results in decreased global and MTHFR north shore methylation in individuals with the 279 
MTHFR 677TT genotype. Consistent with these findings, higher homocysteine levels, 280 
indicative of perturbed B-vitamin status, were significantly reduced and riboflavin status 281 
improved following riboflavin supplementation. This provides some evidence for a 282 
mechanism in which supplementation with riboflavin influenced metabolite levels, and thus 283 
DNA methylation potential. In addition, at baseline, significant hypermethylation was 284 
observed in LINE-1 and MTHFR south shelf methylation in individuals with the MTHFR 285 
677TT genotype compared to individuals with the CC genotype. 286 
 In comparison to folate, one of the main substrates used for generation of methyl groups in 287 
one-carbon metabolism, which has been studied extensively in relation to DNA methylation 288 
[43] the role of riboflavin has been largely overlooked. The evidence regarding the role of 289 
folate on DNA methylation is not entirely consistent. Some previous studies [44–46], 290 
reported that supplementation with folic acid or improved folate status increased global DNA 291 
methylation across a range of tissues, including whole blood, leukocytes and colonic mucosa, 292 
while more recent studies [42,47–49] examining both global, LINE-1 and genome-wide 293 
methylation, including from our own labs, indicate that increased folic acid intake results in 294 
lower DNA methylation. DNA methylation was assessed in whole blood, leukocyte samples 295 
and cord blood in the studies above showing that the findings of inverse association were 296 
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present irrespective of the tissue examined. The results of these recent studies are similar to 297 
our findings which demonstrate an inverse relationship between riboflavin and DNA 298 
methylation in leukocytes as indicated by decreases in both LINE-1 and MTHFR north shore 299 
methylation in response to riboflavin supplementation. Additionally, in general agreement 300 
with the results of this study, Van den Donk et al [50], reported higher dietary folate intake 301 
was associated with lower methylation in whole blood and adenoma tissue in individuals with 302 
the MTHFR 677TT genotype. 303 
Concordant with the findings of the present work, a recent genome-wide methylation study 304 
by Chamberlain et al. [16] reported an inverse association between dietary intake of 305 
riboflavin and LINE-1 methylation in blood samples. The authors did not however measure 306 
biomarker status of riboflavin thus the results should be interpreted with caution. The study 307 
also showed low riboflavin intake to be associated with higher CpG site-specific methylation 308 
at the first exon of the PROM1 locus although no significant associations were observed for 309 
other nutrients involved in one-carbon metabolism including folate, vitamin B-12 and vitamin 310 
B-6 or the methyl donor index, [16]. The “methyl donor index” was calculated as the sum of 311 
the standardised intake values on the log scale [(value − mean)/SD] across 7 individual 312 
nutrients namely riboflavin, vitamin B6, folate, vitamin B12, choline, betaine, and 313 
methionine which are considered to contribute to DNA methylation.  314 
Several factors could account for the inverse relationship between riboflavin biomarker 315 
concentration and both LINE-1 and MTHFR north shore DNA methylation. Methyl groups 316 
generated from one-carbon metabolism are used in a wide range of biological processes and 317 
the complexity in the interactions of these systems implies that there may not necessarily 318 
exist a linear relationship between nutrients involved in one-carbon metabolism and DNA 319 
methylation [43,51]. For example, simple correlations such as high riboflavin status leading 320 
to increased DNA methylation are unlikely to broadly apply and may differ based on cellular 321 
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conditions, dose of riboflavin administered and health status of participants. Secondly, 322 
channelling of methyl groups into DNA methylation is dependent on DNA methyltransferase 323 
enzymes (DNMTs) which tightly regulate the process [52–55]; therefore, an abundance of 324 
methyl groups available for DNA methylation does not necessarily result in increased DNA 325 
methylation. Methyl groups may be directed towards other methylation pathways such as 326 
RNA and histone methylation based on prioritization of cellular conditions and requirements. 327 
A small fraction may also be diverted to non-CG methylation (mostly CpH where H = A,C or 328 
T) which has been detected in almost all tissues tested to date [56]. Similarly, interplay 329 
between DNMTs and transcription factors may potentially influence DNA methylation [57]. 330 
Through interaction with DNMTs, transcription factors influence the establishment and 331 
maintenance of DNA methylation [58,59]. Furthermore, regulation of  DNA methylation by 332 
DNMTs is highlighted in a recent study of polymorphisms in genes involved in one-carbon 333 
metabolism which revealed a significant association between functional polymorphisms of 334 
DNMT3B and MTHFR methylation [60]. In addition, a study of 2,453 individuals from eight 335 
European countries, investigating variables that may have potential impact on DNMT 336 
expression, reported  associations between intake of dairy foods (which are a rich source of 337 
riboflavin) and DNMT1 expression [61], suggesting an additional pathway through which 338 
riboflavin can modulate DNA methylation.  339 
Furthermore, the production of methyl groups for methylation is also dependent on other 340 
enzymes and one-carbon metabolism nutrients such vitamin B-12 and folate. For example, 341 
vitamin B-12 dependent methionine synthase enzyme functions in the remethylation of 342 
homocysteine to methionine and subsequently, the generation of SAM [62]. Therefore, while 343 
it is possible that the MTHFR enzyme may be stabilized by providing riboflavin [20], other 344 
nutrients and enzymes within one-carbon metabolism could impact the production and 345 
availability of methyl groups necessary for DNA methylation. As a first crucial step in 346 
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demonstrating that riboflavin modulates DNA methylation, we show that riboflavin resulted 347 
in decreased total homocysteine, providing important data to support a potential mechanism 348 
whereby riboflavin influences metabolite levels with potential effects on DNA methylation. 349 
Hypermethylation at the MTHFR south shelf in MTHFR 677TT individuals may reflect an 350 
increased demand for protein production to compensate for the reduced stability and activity 351 
of the enzyme [20] in the TT genotype.  Methylation within gene bodies, where the south 352 
shelf is located, is associated with higher-level transcription generally. Though exact 353 
mechanisms are not yet clear, it may prevent aberrant transcription of short transcripts and 354 
thereby direct translation of full-length messenger RNAs [4].  Methylation at the MTHFR 355 
south shelf remains unchanged following riboflavin intervention and may therefore be 356 
important in preventing aberrant MTHFR transcript production in individuals with the TT 357 
genotype.  Global hypermethylation observed in individuals with the MTHFR 677TT 358 
genotype in this study at LINE-1 repetitive elements is also observed in patients with diseases 359 
such as multiple sclerosis and Alzheimer’s compared to healthy controls [63–65]. 360 
While the differences observed in DNA methylation between the MTHFR genotypes in this 361 
study were small, they are comparable with those reported in other studies investigating 362 
LINE-1 methylation in peripheral blood in atherosclerosis, cancer and benzene exposure 363 
[40,66,67]. The changes in methylation elicited by riboflavin supplementation are also similar 364 
to findings of studies investigating other B-vitamins and DNA methylation [68,69]. It is 365 
postulated therefore that the small but significant changes observed may be able to mediate 366 
changes in gene expression and could be reflective of important alterations in the epigenome, 367 
especially in at-risk populations such as individuals with the MTHFR 677TT genotype. In 368 
support of this, it has been shown that drug treatment of cell lines which produced relatively 369 
small methylation changes resulted in transcription changes [70]. Further studies 370 
investigating gene expression and synthesis of the MTHFR protein are required to provide 371 
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further insight into the underlying biological mechanism. We observed decreased methylation 372 
at the MTHFR north shore following supplementation with riboflavin, which has important 373 
implications for gene expression as previous studies have shown that alterations in 374 
methylation at CpG sites within shores display higher correlation to gene expression 375 
compared to CpG islands [3]. As expected, methylation remained unchanged at the MTHFR 376 
CpG island or south shelf following intervention with riboflavin, highlighting the sensitivity 377 
of the MTHFR north shore to nutritional influences in comparison to the south shelf or CpG 378 
island and this could be a potential target for future epigenetic studies.  379 
The major strength of the current study is the inclusion of samples from RCTs incorporating 380 
a parallel placebo group. Importantly, by measuring DNA methylation in the same 381 
individuals before and after supplementation, we can also minimise inter-individual variation 382 
as a source of observed changes in methylation. Furthermore, global and gene-specific 383 
methylation were analysed using the robust pyrosequencing method which has been shown to 384 
be very sensitive and reproducible. In a multicentre benchmarking study evaluating DNA 385 
methylation assays for clinical use, pyrosequencing of repetitive elements including LINE-1 386 
provided highly reproducible results and bisulphite pyrosequencing showed the best 387 
performance for assay sensitivity [71]. Our results however highlight the need for further 388 
work as DNA methylation was examined at a limited number of CpG sites. Therefore, it is 389 
likely that other regions of the genome which are also influenced by riboflavin require further 390 
investigation. Further, while DNA methylation in blood is reflective of methylation status in 391 
other tissues, blood consists of a mixed cell population and further work is required to 392 
completely exclude the possibility that this contributed to the changes in methylation 393 
observed here. We acknowledge that the current study does not allow us to determine tissue-394 
specific effects of riboflavin supplementation on DNA methylation that may be present, the 395 
technique used for assessing DNA methylation does not allow us  they may be undetected in 396 
17 
 
the current study. The present study was confined to investigating the effect of riboflavin on 397 
DNA methylation in adults with the variant TT genotype; future studies should include 398 
individuals with the CC genotype to confirm that the effects observed are genotype driven 399 
which would help to provide some additional mechanistic insights into the role of this gene-400 
nutrient interaction in modifying DNA methylation. 401 
In conclusion, this study is the first to provide RCT evidence demonstrating a novel role for 402 
riboflavin in modulating DNA methylation in adults with the MTHFR 677TT genotype. 403 
Supplementation with riboflavin resulted in decreased global and MTHFR north shore 404 
methylation in TT individuals. Further studies of genome-wide DNA methylation in both TT 405 
and non-TT genotypes, as well as gene expression analysis are required to fully elucidate the 406 
role of riboflavin in modulating the epigenome. 407 
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General characteristics of participants for observational study grouped according to the 
MTHFR C677T genotype at baseline (n 80) 
 MTHFR Genotype 
 MTHFR 677 CC 
(n 40) 
MTHFR 677 TT 
(n 40) 
p-value 
Age (yr) 58.3(3.9) 56.8(6.9) 0.215 
Male n (%) 22(55.5) 24(60.0) 0.651 
Smoker n (%) 5(12.5) 6(15.0) 0.745 
Alcohol (%) 28(70.0) 26(65.0) 0.633 
Hypertensive BP n (%) 12(30.0) 22(55.0) 0.024 
BMI (kg/m2) 29.5(4.8) 29.8(4.8) 0.769 
 
B-vitamin biomarker status  
EGRac 1.34(0.17) 1.34(0.12) 0.945 
Homocysteine (μmol/L) 10.6(3.5) 13.8(4.8) 0.002 
Data are expressed as mean (SD) for continuous variables and frequency (%) for categorical 
variables. Categorical variables analysed using chi square statistics and continuous data were 
analysed using independent t-tests with, p < 0.05 considered statistically significant (significant 
p-values shown in boldface). Hypertension (baseline) defined as BP readings 
(systolic/diastolic) 140mmHg and/or 90mmHg or greater.  















Baseline global and MTHFR gene methylation stratified by the MTHFR C677T genotype (n 
80) 
  DNA methylation (%) 









CpG2 65.82(4.02) 68.34(3.28) 0.002 
CpG3 66.51(3.70) 68.59(5.06) 0.033 
Average 68.86(2.71) 70.44(3.41) 0.011 
 




















MTHFR CpG island 
   
 
CpG1 1.17(0.36) 1.64(1.50) 0.120 
CpG2 0.66(0.31) 0.88(0.60) 0.020 
CpG3 0.57(0.38) 0.86(1.10) 0.241 
Average 0.80(0.32) 1.13(1.04) 0.107 
Data are expressed as mean (SD). Data analysed using one-way ANCOVA adjusting for age, 
sex, smoking status and study cohort with p < 0.05 considered statistically significant.  














Table 3.  
Biomarker response to riboflavin intervention in adults with the MTHFR 677TT genotype (n 
80) 

















































Data expressed as mean (SD). EGRac, biomarker of riboflavin status; a higher value indicates lower 
status. *P-values refer to the time×treatment interaction of the mixed between-within repeated 
measures ANOVA, comparing the effect of treatment vs placebo over time. ǂP-values refer to the 
time×treatment interaction of the repeated measures ANOVA, comparing the effect of treatment vs 
placebo over time with adjustment for baseline homocysteine.  P < 0.05 considered statistically 
significant are shown in bold.  









Effect of riboflavin supplementation on global and MTHFR gene DNA methylation in participants with the MTHFR 677TT genotype (n 80) 
























































































































Data are expressed as mean (SD). Data analysis conducted using mixed between-within repeated measures of ANCOVA adjusting for age, sex, smoking 
status and study cohort as covariates. P-values represent time×treatment interaction comparing the effect of treatment vs placebo over time, with between 
factor as intervention group (riboflavin versus placebo) and within factor as time (pre and post- intervention). ǂP < 0.0125 or *P < 0.008, considered 
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statistically significant after adjusting for Bonferroni correction at assay level (n = 4 for LINE-1, n = 6 for MTHFR north shore, south shelf and CpG island). 
Significant P-values are shown in bold font. aChange in methylation in response to supplementation with riboflavin or placebo was calculated as the 
difference between post-intervention and baseline methylation values.  




Figure 1. One-carbon metabolism pathway.  
Abbreviations: BHMT, betaine-homocysteine s-methyltransferase; DMG, dimethylglycine; 
DNMT, DNA methyltransferase; FAD, flavin adenine dinucleotide (a form of riboflavin); 
FMN, flavin mononucleotide; MAT, methionine adenosyltransferase; PLP, Pyridoxal-5’-
phosphate; SAH, S-adenosylhomocysteine  
Figure 2. Flow diagram of study design investigating DNA methylation.  
The observation component of the study (n = 80) compared DNA methylation between the TT 
and CC genotypes for the MTHFR C677T polymorphism. The intervention stage (n = 80) 
investigated alterations in DNA methylation in participants with the TT genotype in response 
to supplementation with 1.6mg/day of riboflavin or placebo for 16 weeks.  
1Samples were drawn from  the following studies: Genetic and Vitamin study (Genovit) n = 
14; the Genetic and Vitamin ten year follow up study (GENOVIT10) n = 19; and the 
optimization of RIBOflavin Status in Hypertensive Adults with a Genetic predisposition to 
Elevated Blood pressure study (RIBOGENE), n = 87. 
Figure 3. Correlation between riboflavin biomarker status (EGRac) and LINE-1 DNA 
methylation stratified by treatment groups. A lower EGRac value indicates improved riboflavin 
biomarker status. Correlations were estimated using Pearson’s bivariate correlation coefficient 
(r), with p-value < 0.05 considered statistically significant.  
Abbreviations: EGRac, Erythrocyte glutathione reductase activation coefficient; LINE-1, 
long interspersed nuclear element 
Supplementary Figure 1. UCSC genome browser representation of the 5’ region of the 
MTHFR RefSeq gene present in human chromosome 1.  
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A) Chromosome ideogram of chromosome 1 showing the location of the MTHFR gene. B) 
Expanded view of the MTHFR locus on chromosome 1 (p36.22). MTHFR regions analysed by 
pyrosequencing are represented by solid black horizontal bars. MTHFR Ref Seq gene shown 
in dark blue, exons are indicated by solid blue boxes and introns by the blue line with arrows.  
The CpG island present at the 5’ MTHFR region is shown as a green horizontal bar. C) 
ENCODE 450K array datasets indicate variable methylation in the MTHFR north shore and 
south shelf CpGs in various human cell lines, while those in the CpG island are largely 
unmethylated. (GM12878 B lymphocyte; H1-hESC embryonic stem cell; K562 lymphoblast 
chronic myeloid leukaemia; HeLa S3 cervical cancer; HepG2 liver cancer; HUVEC umbilical 
epithelial cells). The CpG positions assayed by these methods are represented as vertical bars 
coloured according to their methylation status; orange = fully methylated (beta value ≥ 0.6), 
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